If ACH-3422 is an “enhanced Sovaldi” (as you claim), how can ACH-3422 be a good fit with a portfolio that already includes Harvoni as well as Sovaldi?
Yes, I believe ACH 3422 will every bit as good as sovaldi in this trial and in future trials ... and I agree with you ... I have never seriously thought GILD to be an ACHN acquirer ... for one thing, they could run afoul of anti-trust laws ... I see a better fit of ACHN with BMY and Roche in particular ...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.